WeedLife News Network
DEA Stops Cannabis Research; Tribes Transiting Unchecked
WASHINGTON, DC / ACCESS Newswire / June 23, 2025 / The U.S. Drug Enforcement Administration (DEA) continues to obstruct legally compliant cannabis research for debilitating conditions like Multiple Sclerosis (MS) and Huntington's Disease (HD)-even as marijuana distribution networks tied to tribal transit operations in North Carolina move quantities of cannabis across state lines with little to no DEA enforcement.
MMJ BioPharma Cultivation, a Rhode Island-based biopharmaceutical company, has 2,375 days working with the FDA and the DEA to bring to market a pharmaceutical-grade cannabinoid soft gelatin capsule for patients in need. Despite holding orphan drug designation from the FDA and full compliance with the Controlled Substances Act, MMJ's bulk manufacturing registration remains unjustifiably denied.
"While MMJ has followed every rule, built an FDA-compliant supply chain, and worked transparently with regulators, the DEA has chosen to prioritize obstruction over innovation," said Duane Boise, CEO of MMJ BioPharma. "Meanwhile, tribal-linked transit networks not subject to proper DEA scrutiny are distributing untaxed and unregulated marijuana across the country. Where is the oversight?"
Copyright
©420 Intel
When you subscribe to the blog, we will send you an e-mail when there are new updates on the site so you wouldn't miss them.
